Self‐Amplified Nanomedicine Enables Lysosomal Blockade to Potentiate Starvation Therapy of Pancreatic Ductal Adenocarcinoma
Advanced Materials · 2026
DOI: 10.1002/adma.202519523 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2026. Verfasst von Mingjie Song und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing, China. Hauptthemen laut MEDLINE: Lysosomes, Carcinoma, Pancreatic Ductal, Nanomedicine, Pancreatic Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: National Ten Thousand Talents Program for Young Top-notch Talents, Natural Science Foundation Outstanding Youth Fund of Jiangsu Province, Jiangsu 333 High-level Talent Training Project.
Abstract (Originalsprache)
Starvation therapy targeting the metabolic vulnerability of pancreatic ductal adenocarcinoma (PDAC) holds great potential; however, analyses of clinical samples and orthotopic models reveal that its efficacy is undermined by lysosome‐mediated metabolic compensation. To disrupt this metabolic adaptability, we herein engineer a homotypic membrane‐camouflaged nanomedicine capable of hypoxia‐responsive cascade drug release and enhanced tumor accumulation. The resulting nanomedicine performs a hypoxia‐induced phase transition that first liberates glucose oxidase to intensify oxygen deprivation and subsequently triggers burst release of chloroquine. Such a design of self‐amplified relay drug release ensures effective starvation induction and precise lysosomal alkalization, thereby shutting down lysosome‐mediated nutrient recycling. In a xenograft orthotopic PDAC model, this nanomedicine achieves 9.75‐fold increase in tumor accumulation, robust tumor inhibition of 92.8%, and an elevated survival rate of 80% with favorable biosafety. Collectively, our findings highlight lysosomal disruption as a therapeutic lever to potentiate starvation therapy and provide a clinically actionable nanoplatform to enhance metabolic interventions for other metabolically vulnerable malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing, China.
- Department of Hepato-Biliary-Pancreatic Surgery, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu, China.
- Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University, Nanjing, China.
ORCID-Profile: Yang Ding
Förderung
- National Ten Thousand Talents Program for Young Top-notch Talents
- Natural Science Foundation Outstanding Youth Fund of Jiangsu Province
- Jiangsu 333 High-level Talent Training Project
- Postgraduate Research & Practice Innovation Program of Jiangsu Province
- National Natural Science Foundation of China
- Youth Elite Scientists Sponsorship Program by CAST
- Zhejiang Provincial Natural Science Foundation of China under Grant
- Research Project of Lingang National Laboratory
Zitieren
APA
Song, M., Zhang, Z., Pan, X., Yang, X., Xu, F., Ye, Z., Zhou, J., Zhong, Q., Ding, Y., & Zhang, H. (2026). Self‐Amplified Nanomedicine Enables Lysosomal Blockade to Potentiate Starvation Therapy of Pancreatic Ductal Adenocarcinoma. Advanced Materials. https://doi.org/10.1002/adma.202519523
Vancouver
Song M, Zhang Z, Pan X, Yang X, Xu F, Ye Z, et al. Self‐Amplified Nanomedicine Enables Lysosomal Blockade to Potentiate Starvation Therapy of Pancreatic Ductal Adenocarcinoma. Advanced Materials. 2026. doi:10.1002/adma.202519523
BibTeX
@article{Song2026,
author = {Song, Mingjie and Zhang, Ziru and Pan, Xuan and Yang, Xiaoyu and Xu, Fenglin and Ye, Zhenning and Zhou, Jianping and Zhong, Qifeng and Ding, Yang and Zhang, Huaqing},
title = {Self‐Amplified Nanomedicine Enables Lysosomal Blockade to Potentiate Starvation Therapy of Pancreatic Ductal Adenocarcinoma},
journal = {Advanced Materials},
year = {2026},
doi = {10.1002/adma.202519523}
}
EUVIMED